Table 4:
Acute and late toxicity for RTOG and CTCAE scales
| Acute toxicity | Entire Cohort (n=120) |
|---|---|
| Skin toxicity CTCAE | |
| 0 | 34 (28%) |
| 1 | 77 (64%) |
| 2 | 9 (8%) |
| 3 | 0 |
| 4 | 0 |
| 5 | 0 |
| Fatigue CTCAE | |
| 0 | 69 (58%) |
| 1 | 49 (41%) |
| 2 | 2 (2%) |
| 3 | 0 |
| 4 | 0 |
| 5 | 0 |
| Pain CTCAE | |
| 0 | 73 (61%) |
| 1 | 34 (28%) |
| 2 | 13 (11%) |
| 3 | 0 |
| 4 | 0 |
| 5 | 0 |
| Late toxicity | Patients with ≥ 6 months of follow up (n=115) |
| Skin RTOG | |
| 0 | 71 (62%) |
| 1 | 41 (36%) |
| 2 | 2 (2%) |
| 3 | 0 |
| 4 | 1 (1%) |
| Fibrosis of superficial or deep connective tissue CTCAE | |
| 0 | 84 (73%) |
| 1 | 28 (24%) |
| 2 | 3 (3%) |
| 3 | 0 |
| 4 | 0 |
| 5 | 0 |
| Lymphedema CTCAE | |
| 0 | 98 (85%) |
| 1 | 14 (12%) |
| 2 | 2 (2%) |
| 3 | 1 (1%) |
| 4 | 0 |
| 5 | 0 |
| Joint CTCAE | |
| 0 | 91 (79%) |
| 1 | 24 (21%) |
| 2 | 0 |
| 3 | 0 |
| 4 | 0 |
| 5 | 0 |
*
Late toxicity at last follow-up; 5 patients missing due to death before 6 months (n=3) or duration of follow-up for toxicity assessment < 6 months (n=2).